Cargando…

Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products

The standardized mean difference is a well‐known effect size measure for continuous, normally distributed data. In this paper we present a general basis for important other distribution families. As a general concept, usable for every distribution family, we introduce the relative effect, also calle...

Descripción completa

Detalles Bibliográficos
Autores principales: Rahlfs, Volker, Zimmermann, Helmuth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618136/
https://www.ncbi.nlm.nih.gov/pubmed/30821037
http://dx.doi.org/10.1002/bimj.201800107
_version_ 1783433851071102976
author Rahlfs, Volker
Zimmermann, Helmuth
author_facet Rahlfs, Volker
Zimmermann, Helmuth
author_sort Rahlfs, Volker
collection PubMed
description The standardized mean difference is a well‐known effect size measure for continuous, normally distributed data. In this paper we present a general basis for important other distribution families. As a general concept, usable for every distribution family, we introduce the relative effect, also called Mann–Whitney effect size measure of stochastic superiority. This measure is a truly robust measure, needing no assumptions about a distribution family. It is thus the preferred tool for assumption‐free, confirmatory studies. For normal distribution shift, proportional odds, and proportional hazards, we show how to derive many global values such as risk difference average, risk difference extremum, and odds ratio extremum. We demonstrate that the well‐known benchmark values of Cohen with respect to group differences—small, medium, large—can be translated easily into corresponding Mann–Whitney values. From these, we get benchmarks for parameters of other distribution families. Furthermore, it is shown that local measures based on binary data (2 × 2 tables) can be associated with the Mann–Whitney measure: The concept of stochastic superiority can always be used. It is a general statistical value in every distribution family. It therefore yields a procedure for standardizing the assessment of effect size measures. We look at the aspect of relevance of an effect size and—introducing confidence intervals—present some examples for use in statistical practice.
format Online
Article
Text
id pubmed-6618136
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66181362019-07-22 Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products Rahlfs, Volker Zimmermann, Helmuth Biom J General Biometry The standardized mean difference is a well‐known effect size measure for continuous, normally distributed data. In this paper we present a general basis for important other distribution families. As a general concept, usable for every distribution family, we introduce the relative effect, also called Mann–Whitney effect size measure of stochastic superiority. This measure is a truly robust measure, needing no assumptions about a distribution family. It is thus the preferred tool for assumption‐free, confirmatory studies. For normal distribution shift, proportional odds, and proportional hazards, we show how to derive many global values such as risk difference average, risk difference extremum, and odds ratio extremum. We demonstrate that the well‐known benchmark values of Cohen with respect to group differences—small, medium, large—can be translated easily into corresponding Mann–Whitney values. From these, we get benchmarks for parameters of other distribution families. Furthermore, it is shown that local measures based on binary data (2 × 2 tables) can be associated with the Mann–Whitney measure: The concept of stochastic superiority can always be used. It is a general statistical value in every distribution family. It therefore yields a procedure for standardizing the assessment of effect size measures. We look at the aspect of relevance of an effect size and—introducing confidence intervals—present some examples for use in statistical practice. John Wiley and Sons Inc. 2019-02-28 2019-07 /pmc/articles/PMC6618136/ /pubmed/30821037 http://dx.doi.org/10.1002/bimj.201800107 Text en © 2019 The Authors. Biometrical Journal Published by WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle General Biometry
Rahlfs, Volker
Zimmermann, Helmuth
Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products
title Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products
title_full Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products
title_fullStr Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products
title_full_unstemmed Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products
title_short Effect size measures and their benchmark values for quantifying benefit or risk of medicinal products
title_sort effect size measures and their benchmark values for quantifying benefit or risk of medicinal products
topic General Biometry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618136/
https://www.ncbi.nlm.nih.gov/pubmed/30821037
http://dx.doi.org/10.1002/bimj.201800107
work_keys_str_mv AT rahlfsvolker effectsizemeasuresandtheirbenchmarkvaluesforquantifyingbenefitorriskofmedicinalproducts
AT zimmermannhelmuth effectsizemeasuresandtheirbenchmarkvaluesforquantifyingbenefitorriskofmedicinalproducts